List of likely buyers of Novartis’ Dermatology division ($2bn) takes shape

A list of likely buyers of Novartis’ US dermatology generics division, valued at an approximate $2bn, is now drawn up, Bloomberg has reported. The list includes China-based Shanghai Fosun Pharmaceutical, Apollo Global Management, CVC Capital Partners and India-based Aurobindo Pharma.  Novartis in January announced that the decision to sell the asset reflects the low profitability due to the price war opposing generics manufacturers in the US.

(Source: Bloomberg)